265 related articles for article (PubMed ID: 35464395)
1. The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.
Becker JP; Riemer AB
Front Immunol; 2022; 13():883989. PubMed ID: 35464395
[TBL] [Abstract][Full Text] [Related]
2. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
Front Immunol; 2018; 9():912. PubMed ID: 29780384
[TBL] [Abstract][Full Text] [Related]
3. What do cancer-specific CD8+ T cells see? The contribution of immunopeptidomics.
Nicholas B; Skipp P
Essays Biochem; 2023 Sep; 67(6):957-965. PubMed ID: 37503576
[TBL] [Abstract][Full Text] [Related]
4. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
5. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
Chikata T; Paes W; Akahoshi T; Partridge T; Murakoshi H; Gatanaga H; Ternette N; Oka S; Borrow P; Takiguchi M
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217245
[TBL] [Abstract][Full Text] [Related]
6. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
ElAbd H; Franke A
Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
[TBL] [Abstract][Full Text] [Related]
7. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
8. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
[TBL] [Abstract][Full Text] [Related]
9. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
Minegishi Y; Haga Y; Ueda K
Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
[TBL] [Abstract][Full Text] [Related]
10. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
11. TOF
Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
[TBL] [Abstract][Full Text] [Related]
12. Antigen discovery for the development of cancer immunotherapy.
Ahn R; Cui Y; White FM
Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147
[TBL] [Abstract][Full Text] [Related]
13. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
14. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
15. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36798179
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.
de Beijer MTA; Jansen DTSL; Dou Y; van Esch WJE; Mok JY; Maas MJP; Brasser G; de Man RA; Woltman AM; Buschow SI
J Virol; 2020 Mar; 94(7):. PubMed ID: 31852786
[TBL] [Abstract][Full Text] [Related]
17. Evaluating performance of existing computational models in predicting CD8+ T cell pathogenic epitopes and cancer neoantigens.
Buckley PR; Lee CH; Ma R; Woodhouse I; Woo J; Tsvetkov VO; Shcherbinin DS; Antanaviciute A; Shughay M; Rei M; Simmons A; Koohy H
Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35471658
[TBL] [Abstract][Full Text] [Related]
18. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
19. IEPAPI: a method for immune epitope prediction by incorporating antigen presentation and immunogenicity.
Deng J; Zhou X; Zhang P; Cheng W; Liu M; Tian J
Brief Bioinform; 2023 Jul; 24(4):. PubMed ID: 37232386
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]